References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-193-9-86-95

nogr-1740

Research Article

ОБЗОР

REVIEW

Роль Helicobacter pylori в развитии метаболических и сердечно-сосудистых заболеваний

The role of Helicobacter pylori in metabolic and cardiovascular diseases

https://orcid.org/0000-0001-5547-6741

Куглер

Т. Е.

Kugler

T. E.

Куглер Татьяна Евгеньевна - кандидат медицинских наук, ассистент кафедры терапии ФИПО им. проф. А. И. Дядыка, Researcher ID: B-1384–2015.

83003 Донецк, проспект Ильича 16

Tatyana E. Kugler - PhD, assistant of A. I. Dyadyk Department of Therapy, Division of Internship and Postgraduate Training, Researcher ID: B-1384–2015.

83003 Donetsk, Illicha av.16

kugler2@mail.ru

https://orcid.org/0000-0003-3984-8482

Тарадин

Г. Г.

Taradin

G. G.

Тарадин Геннадий Геннадиевич – кандидат медицинских наук, доцент, заведующий кафедрой терапии ФИПО им. проф. А. И. Дядыка, Research ID: N-9875–2015.

83003 Донецк, проспект Ильича 16

Gennadiy G. Taradin - PhD, Chief of the A. I. Dyadyk Department of Therapy, Division of Internship and Postgraduate Training, Research ID: N-9875–2015.

83003 Donetsk, Illicha av.16

https://orcid.org/0000-0003-3438-0649

Пеликано

Р.

Pellicano

Pellicano Rinaldo – доктор медицинских наук, отделение гастроэнтерологии, Scopus Author ID: 7005853671.

10126 Турин, Via Cavour 31

Rinaldo Pellicano - MD, Unit of Gastroenterology, Scopus Author ID: 7005853671.

10126 Turin, Via Cavour 31

Государственная образовательная организация высшего профессионального образования Донецкий национальный медицинский университет имени М. ГорькогоУкраинаM. Gorky Donetsk National Medical UniversityUkraine

Больница Молинетт и Сан-Джованни-Антика-СедеИталияMolinette and San Giovanni Antica sede HospitalItaly

2021

10122021

098695

2021

Куглер Т.Е., Тарадин Г.Г., Пеликано Р.

Kugler T.E., Taradin G.G., Pellicano R.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/1740

Инфекция Helicobacter pylori (H. pylori) является одной из наиболее распространенных в мире. Инфицированность населения земного шара превышает 50% и особенно высока в странах с низким социально-экономическим уровнем развития. H. pylori способна вызывать гастродуоденальные и экстрагастродуоденальные заболевания, в частности такие метаболические нарушения, как ожирение, сахарный диабет и неалкогольная жировая болезнь печени. Недавние эпидемиологические и клинические исследования также показали, что длительная персистенция H. pylori связана с развитием и прогрессированием атеросклероза и как следствие - возникновением сердечно-сосудистых заболеваний. Однако связь между ними неоднозначна и в литературе нет убедительных доказательств этой корреляции. Отсутствие консенсуса может быть связано с различиями в диагностике H. pylori и вариабельностью генотипов инфекции. Учитывая высокую распространенность H. pylori и значительную частоту метаболических и сердечно-сосудистых заболеваний, подтверждение связи между ними может иметь большое эпидемиологическое, профилактическое и клиническое значение.

Helicobacter pylori (H. pylori) infection is one of the most common in the world. More than 50% of the world’s population is infected and infection rates are especially high in countries with poor socio-economic conditions. H. pylori causes gastroduodenal and extra-gastroduodenal diseases including such metabolic disorders as obesity, diabetes mellitus and non-alcoholic fatty liver disease. Recent epidemiological and clinical studies showed that the long-term persistence of H. pylori infection is associated with the development and progression of atherosclerosis and consequently cardiovascular diseases. However, the correlation between these conditions is ambiguous and there is not enough evidence to confirm it. The lack of consensus might be related to differences in diagnostic methods used for H. pylori and the variety of its genotypes. Considering high prevalence of H. pylori infection as well as high incidence of metabolic and cardiovascular diseases, a verified correlation between these can be of great epidemiological, prophylactic and clinical significance.

Helicobacter pyloriожирениесахарный диабетнеалкогольная жировая болезнь печениишемическая болезнь сердцаатеросклерозхолестерининсулинорезистентностьглюкоза

Helicobacter pyloriobesitydiabetes mellitusnon-alcoholic fatty liver diseasecoronary heart diseaseatherosclerosischolesterolinsulin resistanceglucose

References1

Santos M.L.C., de Brito B. B., da Silva F. A.F., Sampaio M. M. et al. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol. 2020; 26(28): 4076-4093. doi: 10.3748/wjg.v26.i28.4076.

Rogha M., Nikvarz M., Pourmoghaddas Z., Shirneshan K. et al. Is Helicobacter pylori infection a risk factor for coronary heart disease? ARYA Atheroscler. 2012 Spring;8(1):5-8. PMID: 23056092; PMCID: PMC3448393.

Дядык А. И., Куглер Т. Е. Кардиоваскулярные, ренальные и нейропсихические побочные эффекты эрадикационной терапии Helicobacter pylori. Лечащий врач; 2017. 8: 32-35.

Dyadyk A.I., Kugler T. E. Cardiovascular, renal and neuropsychiatric side effects of Helicobacter pylori eradication therapy. Lechashii vrach. 2017; 8: 32-35. (in Russ.)

Pellicano R., Ianiro G., Fagoonee S., Settanni C. R., et al. Review: Extragastric diseases and Helicobacter pylori. Helicobacter. 2020; 25 (Suppl. 1): e12741. doi: 10.1111/hel.12741.

Gravina A.G., Zagari R. M., De Musis C., Romano L., et al. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018; 24(29): 3204-3221 doi: 10.3748/wjg.v24.i29.3204.

Mansori K., Moradi Y., Naderpour S., et al. Helicobacter pylori infection as a risk factor for diabetes: a meta-analysis of case-control studies. BMC Gastroenterology. 2020; 77: 1-14. doi: 10.1186/s12876-020-01223-0.

Cuomo P., Papaianni M., Sansone C., Iannelli A. et al. An In Vitro Model to Investigate the Role of Helicobacter pylori in Type 2 Diabetes, Obesity, Alzheimer’s Disease and Cardiometabolic Disease. Int J Mol Sci. 2020; 21(21): 8369. doi: 10.3390/ijms21218369.

Mladenova I., Durazzo M. Transmission of Helicobacter pylori. Minerva Gastroenterol Dietol. 2018 Sep;64(3):251-254. doi: 10.23736/S1121-421X.18.02480-7.

Reshetnyak V.I., Burmistrov A. I., Maev I. V. Helicobacter pylori: Commensal, symbiont or pathogen? World J Gastroenterol. 2021; 27(7): 545-560. doi:10.3748/wjg.v27.i7.545.

Censini S., Stein M., Covacci A. Cellular responses induced after contact with Helicobacter pylori. Curr Opin Microbiol. 2001 Feb;4(1):41-6. doi: 10.1016/s1369-5274(00)00162-4.

El-Omar E.M., Carrington M., Chow W. H., McColl K. E., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000 Mar 23;404(6776):398-402. doi: 10.1038/35006081.

Успенский Ю. П., Барышникова Н. В. Инфекция Helicobacter pylori и метаболические нарушения: есть ли связь? Экспериментальная и клиническая гастроэнтерология. 2017; 143 (7): 107-114.

Uspenskiy Yu.P., Baryshnikova N. V. Helicobacter pylori infection and metabolic disorders: is the link? Experimental and Clinical Gastroenterology. 2017; 143 (7): 107-114. (In Russ.)

Маев И. В., Бакулин И. Г., Курилович С. А., Бакулина Н. В. и соавт. Helicobacter pylori и экстрагастродуоденальные заболевания: доказанные факты и предположения. Доказательная гастроэнтерология. 2018; 3: 45-58. doi: 10.17116/dokgastro2018703145.

Maev I.V., Bakulin I. G., Kurilovich S. A., Bakulina N. V. Helicobacter pylori and extragastroduodenal diseases: the proven facts and assumptions. Russian Journal of Evidence-Based Gastroenterology. 2018;7(3):45-59. (In Russ.) doi: 10.17116/dokgastro2018703145.

Erol A., Atılgan H., Yavaşoğlu I. The prevalence of Helicobacter pylori in obese subjects. European Journal of Internal Medicine. 2009 Nov;20(7):695-7. doi: 10.1016/j.ejim.2009.07.013.

Lender N., Tally N. J., Enck P., Haag S., et al. Review article: Associations between Helicobacter pylori and obesity - an ecological study. Alimentary Pharmacology & Therapeutics. 2014 Jul;40(1):24-31. doi: 10.1111/apt.12790.

Wawro N., Amann U., Butt J., et al. Helicobacter pylori seropositivity: prevalence, associations, and the impact on incident metabolic diseases/risk factors in the population-based KORA Study. Front Public Health. 2019 Apr 24;7:96. doi: 10.3389/fpubh.2019.00096.

Lim S.H., Kim N., Kwon J. W., et al. Positive association between Helicobacter pylori infection and metabolic syndrome in a Korean population: a Multicenter Nationwide Study. Dig Dis Sci. 2019 Aug;64(8):2219-2230. doi: 10.1007/s10620-019-05544-3.

Yu Y., Cai J., Song Z., Wang J., et al. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females. Exp Ther Med. 2019 Jun;17(6):4403-4408. doi: 10.3892/etm.2019.7509.

Xu X., Li W., Qin L., Yang W., Yu G., Wei Q. Relationship between Helicobacter pylori infection and obesity in Chinese adults: a systematic review with meta-analysis. PLoS One. 2019 Sep 11;14(9): e0221076. doi: 10.1371/journal.pone.0221076.

Liu R., Liu Q., He Y., Shi W., et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. Medicine (Baltimore). 2019 Nov;98(44): e17781. doi: 10.1097/MD.0000000000017781.

Герман С. В., Бобровницкий И. П. Инфекция Helicobacter pylori и гепатобилиарная патология. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(4):15-22. doi: 10.22416/1382-4376-2018-28-4-15-22.

German S.V., Bobrovnitsky I. P. Helicobacter pylori Infection and Hepatobiliary Pathology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018; 28(4):15-22. (In Russ.) doi: 10.22416/1382-4376-2018-28-4-15-22.

Лазебник Л. Б., Тарасова Л. В., Комарова Е. А., Бусалаева Е. И. Влияние инфекции Helicobacter pylori на течение неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2019;172(12): 90-94. DOI: 10.31146/1682-8658-ecg-172-12-90-94.

Lazebnik L. B., Tarasova L. V., Komarova Е. A., Busalayeva E. I. Effect of Helicobacter pylori infection on the course of nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;172(12): 90-94. (In Russ.) DOI: 10.31146/1682-8658-ecg-172-12-90-94.

Сарсенбаева А. С., Уфимцев К. А., Домрачева Е. В. Инфекция Helicobacter pylori и жировая инфильтрация печени. Экспериментальная и клиническая гастроэнтерология. 2020;178(6): 146-153. DOI: 10.31146/1682-8658-ecg-178-6-146-153.

Sarsenbaevа A.S., Ufimtsev К. А., Domracheva E. V. Helicobacter pylori infection and fatty liver. Experimental and Clinical Gastroenterology. 2020; 178(6): 146-153. (In Russ.) DOI: 10.31146/1682-8658-ecg-178-6-146-153.

Mantovani A., Turino T., Altomari A., et al. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: an updated meta-analysis. Metabolism. 2019 Jul;96:56-65. doi: 10.1016/j.metabol.2019.04.012.

Zhou B.G., Yang H. J., Xu W., Wang K., et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systematic review and meta-analysis of observational studies. Helicobacter. 2019 Jun;24(3): e12576. doi: 10.1111/hel.12576.

Ning L., Liu R., Lou X., et al. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):735-742. doi: 10.1097/MEG.0000000000001398.

Abo-Amer Y.E., Sabal A., Ahmed R., et al. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease (NAFLD) in a developing country: a cross-sectional study. Diabetes Metab Syndr Obes. 2020 Mar 2;13:619-625. doi: 10.2147/DMSO.S237866.

Abdel-Razik A., Mousa N., Elhelaly R., et al. Helicobacter pylori as an initiating factor of complications in patients with cirrhosis: a single-center observational study. Front Med (Lausanne). 2020 Mar 24;7:96. doi: 10.3389/fmed.2020.00096.

Pellicano R., Ménard A., Rizzetto M., Mégraud F. Helicobacter species and liver diseases: association or causation? Lancet Infect Dis. 2008 Apr;8(4):254-60. doi: 10.1016/S1473-3099(08)70066-5.

Shaw J.E., Sicree R. A., Zimmet P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007.

Chen Y., Blaser M. J. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J. Infect. Dis. 2012; 205:1195-1202. doi: 10.1093/infdis/jis106.

Gunji T., Matsuhashi N., Sato H., Fujibayashi K., et al. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter. 2009; 14:144-150. doi: 10.1111/j.1523-5378.2009.00705.x.

Jeon C.Y., Haan M. N., Cheng C., Clayton E. R., et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care. 2012; 35:520-525. doi: 10.2337/dc11-1043.

Wang F., Fu Y., Lv Z. Association of Helicobacter pylori infection with diabetic complications: A meta-analysis. Endocr. Res. 2014; 39:7-12. doi: 10.3109/07435800.2013.794426.

Kim T.J., Lee H., Kang M., Kim J. E., et al. Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease. Sci. Rep. 2016; 6:38015. doi: 10.1038/srep38015.

Wada Y., Hamamoto Y., Kawasaki Y., Honjo S., et al. The eradication of Helicobacter pylori does not affect glycemic control in japanese subjects with type 2 diabetes. Jpn. Clin. Med. 2013; 4:41-43. doi: 10.4137/JCM.S10828.

Chen J., Xing Y., Zhao L., Ma H. The association between Helicobacter pylori infection and glycated hemoglobin A in diabetes: a meta-analysis. J Diabetes Res. 2019; 2019:3705264.

Li J.Z., Li J. Y., Wu T. F., et al. Helicobacter pylori infection is associated with type 2 diabetes, not type 1 diabetes: an updated meta-analysis. Gastroenterol Res Pract. 2017;2017:5715403. doi: 10.1155/2017/5715403.

Wang F, Liu J, Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. Scand J Infect Dis. 2013 Dec;45(12):930-8. doi: 10.3109/00365548.2013.844351.

Zhou X., Zhang C., Wu J., Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. Diabetes Res Clin Pract. 2013 Feb;99(2):200-8. doi: 10.1016/j.diabres.2012.11.012.

Wan Z., Song L., Hu L., et al. Helicobacter pylori infection is associated with diabetes among Chinese adults. J Diabetes Invest. 2020 Jan;11(1):199-205. doi: 10.1111/jdi.13102.

Hsieh M.C., Wang S. S., Hsieh Y. T., Kuo F. C., et al. Helicobacter pylori infection associated with high H b a 1c and type 2 diabetes. Eur J Clin Investig. 2013 Sep;43(9):949-56. doi: 10.1111/eci.12124.

Song X., Cai C., Jin Q., Chen X., et al. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis. Helicobacter. 2021 Apr; 26(2): e12781. doi: 10.1111/hel.12781.

Cheng K.P., Yang Y. J., Hung H. C., et al. Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection. J Diabetes Investig. 2019 Jul;10(4):1092-1101. doi: 10.1111/jdi.12991.

Vafaeimanesh J., Parham M., Seyyedmajidi M., Bagherzadeh M. Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population. ScientificWorldJournal. 2014;2014:391250. doi: 10.1155/2014/391250.

Chung G.E., Heo N. J., Park M. J., Chung S. J., et al. Helicobacter pylori seropositivity in diabetic patients is associated with microalbuminuria. World J Gastroenterol. 2013 Jan 7;19(1):97-102. doi: 10.3748/wjg.v19.i1.97.

Moretti E., Figura N., Campagna M. S., et al. Sperm parameters and semen levels of inflammatory cytokines in Helicobacter pylori-infected men. Urology. 2015 Jul;86(1):41-6. doi: 10.1016/j.urology.2015.02.068.

Sze M.A., Chen Y. W., Tam S., et al. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015 Oct;70(10):923-9. doi: 10.1136/thoraxjnl-2015-207059.

Zielen S., Trischler J., Schubert R. Lipopolysaccharide challenge: immunological effects and safety in humans. Exp Rev Clin Immunol. 2015 Mar;11(3):409-18. doi: 10.1586/1744666X.2015.1012158.

Klok M.D., Jakobsdottir S., Drent M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007 Jan;8(1):21-34. doi: 10.1111/j.1467-789X.2006.00270.x.

Ronveaux C.C., Tome D., Raybould H. E. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr. 2015 Apr;145(4):672-80. doi: 10.3945/jn.114.206029.

Yang Y.F., Li Y., Liu J. H., et al. Relation of Helicobacter pylori infection to peripheral arterial stiffness and 10-year cardiovascular risk in subjects with diabetes mellitus. Diab Vasc Dis Res. 2020; 17(5):1479164120953626. doi:10.1177/1479164120953626.

Pyo J.H., Lee H., Choi S. C., et al. Lack of association between past Helicobacter pylori infection and diabetes: a two-cohort study. Nutrients. 2019 Aug 12;11(8):1874. doi: 10.3390/nu11081874.

Yang S., Xia Y. P., Luo X. Y., Chen S. L., et al. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis. J Mol Cell Cardiol. 2019 Oct;135:40-51. doi: 10.1016/j.yjmcc.2019.07.011.

Shimamoto T., Yamamichi N., Gondo K., Takahashi Y., et al. The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE. 2020; 15: e0234433. doi: 10.1371/journal.pone.0234433.

Iwai N., Okuda T., Oka K., Hara T., et al. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study. PLoS One. 2019 Aug 16;14(8): e0221349. doi: 10.1371/journal.pone.0221349.

Upala S., Sanguankeo A., Saleem S. A., Jaruvongvanich V. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2017; 29:153-159. doi: 10.1097/MEG.0000000000000774.

Watanabe J., Hamasaki M., Kotani K. The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis. J Clin Med. 2021;10 (5): 904. doi:10.3390/jcm10050904

Liu J., Wang F., Shi S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants. Helicobacter. 2015 Jun;20(3):176-83. doi: 10.1111/hel.12188.

Sun J., Rangan P., Bhat S. S., Liu L. A. Meta-Analysis of the Association between Helicobacter pylori Infection and Risk of Coronary Heart Disease from Published Prospective Studies. Helicobacter. 2016 Feb;21(1):11-23. doi: 10.1111/hel.12234.

Yoshikawa H., Aida K., Mori A., Muto S., et al. Involvement of Helicobacter pylori infection and impaired glucose metabolism in the increase of brachial-ankle pulse wave velocity. Helicobacter. 2007 Oct;12(5):559-66. doi: 10.1111/j.1523-5378.2007.00523.x.

Lee M., Baek H., Park J. S., Kim S., et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One. 2018 Mar 2;13(3): e0193646. doi: 10.1371/journal.pone.0193646.

Figura N., Palazzuoli A., Vaira D., Campagna M., et al. Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol. 2014 Mar;67(3):251-7. doi: 10.1136/jclinpath-2013-201743.

Pietroiusti A., Diomedi M., Silvestrini M., Cupini L. M., et al. Cytotoxin-associated gene-A - positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation. 2002 Jul 30;106(5):580-4. doi: 10.1161/01.cir.0000023894.10871.2f.

Fang Y., Fan C., Xie H. Effect of Helicobacter pylori infection on the risk of acute coronary syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019 Dec;98(50): e18348. doi: 10.1097/MD.0000000000018348.

Choi J.M., Lim S. H., Han Y. M., et al. Association between Helicobacter pylori infection and arterial stiffness: results from a large cross-sectional study. PLoS One. 2019 Aug 29;14(8): e0221643. doi: 10.1371/journal.pone.0221643.

Zhang L., Chen Z., Xia X., et al. Helicobacter pylori infection selectively increases the risk for carotid atherosclerosis in young males. Atherosclerosis. 2019 Dec;291:71-77. doi: 10.1016/j.atherosclerosis.2019.10.005.

Yang Y.F., Li Y., Liu J. H., Wang X. M., et al. Relation of Helicobacter pylori infection to peripheral arterial stiffness and 10-year cardiovascular risk in subjects with diabetes mellitus. Diab Vasc Dis Res. 2020; 17(5):1479164120953626. doi: 10.1177/1479164120953626.

Li N., Liu S. F., Dong K., et al. Exosome-transmitted miR-25 induced by H pylori promotes vascular endothelial cell injury by targeting KLF2. Front Cell Infect Microbiol. 2019 Oct 29;9:366. doi: 10.3389/fcimb.2019.00366.

Камышникова Л. А., Ефремова О. А., Гусейнли Э. Г., Gusejnli E. G. Современный обзор: Helicobacter pylori и риск развития ишемической болезни сердца. Научный результат. Медицина и фармация. 2016; 2 (3): 3-10. doi: 10.18413/2313-8955-2016-2-3-3-10.

Kamyshnikova L.A., Efremova O. A., Gusejnli E. G. Modern review: Helicobacter pylori and risk of coronary heart disease. Nauchnii resultat. Medicina i farmaciya. 2016; 2 (3): 3-10. (In Rus.) doi: 10.18413/2313-8955-2016-2-3-3-10.

Furuto Y., Kawamura M., Yamashita J, et al. Relationship Between Helicobacter pylori Infection and Arteriosclerosis. Int J Gen Med. 2021; 14:1533-1540. doi: 10.2147/IJGM.S303071.

Murray L.J., Bamford K. B., Kee F., et al. Infection with virulent strains of Helicobacter pylori is not associated with ischaemic heart disease: evidence from a population-based case-control study of myocardial infarction. Atherosclerosis. 2000; 149(2): 379-385. doi: 10.1016/S0021-9150(99)00325-1.

Slomiany B.L., Slomiany A. Induction in gastric mucosal prostaglandin and nitric oxide by Helicobacter pylori is dependent on MAPK/ERK-mediated activation of IKK-β and cPLA2: modulatory effect of ghrelin. Inflammopharmacology. 2013; 21(3): 241-251. doi: 10.1007/s10787-013-0169-5.

Ramji D.P., Davies T. S. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015 Dec;26(6):673-85. doi: 10.1016/j.cytogfr.2015.04.003.

Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit Rev Microbiol. 2003;29(4):351-9. doi: 10.1080/713608015.

Nasrat S.A.M, Nasrat A. M. An alternative approach for the rising challenge of hypertensive illness via Helicobacter pylori eradication. Cardiol Res. 2015; 6(1):221-225. doi: 10.14740/cr382e.

Viayvergiya R., Vadivelu R. Role of Helicobacter pylori infection in pathogenesis of atherosclerosis. World J Cardiol. 2015; 7(3):134-143. doi: 10.4330/wjc. v7.i3.134.

Figura N., Palazzuoli A., Vaira D., et al. Cross-sectional study: cagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. J Clin Pathol. 2014; 67(3): 251-257. doi: 10.1136/jclinpath-2013-201743.

Tamura A., Fujioka T., Nasu M. Relation of Helicobacter pylori infection to plasma vitamin B12, folic acid, and homocysteine levels in patients who underwent diagnostic coronary arteriography. Am J Gastroenterol. 2002 Apr;97(4):861-6. doi: 10.1111/j.1572-0241.2002.05601.x.

Kutluana U., Kilciler A. G. Is there a possible relationship between gastric intestinal metaplasia and systemic arterial stiffness? Rev Esp Enferm Dig. 2019 Jul;111(7):500-506. doi: 10.17235/reed.2019.5945/2018.

The authors declare that there are no conflicts of interest present.